GBS(US:INBS) Globenewswire·2025-10-23 12:30Core Insights - Intelligent Bio Solutions Inc. has secured a significant contract with a major industrial service provider in the UK, marking a key milestone in the adoption of its rapid, non-invasive drug testing technology [1][3][5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [7] - The company employs approximately 3,000 staff in the UK and Ireland, with over 30,000 employees globally [1][2] Technology Adoption - The new customer account represents one of the most significant commercial deployments for INBS in the UK, aimed at modernizing workforce safety and compliance [3] - The transition from traditional urine collection methods to INBS's technology is expected to enhance testing efficiency, reduce downtime, and improve productivity [3][4] Market Confidence and Growth - The contract highlights growing market confidence in INBS's technology, which is increasingly being adopted by large industrial operators [5] - INBS's drug testing technology is currently utilized by over 480 accounts across 24 countries, supported by 18 distribution partners [6] Business Model and Revenue Potential - The company's business model is characterized by a "razor–razor-blade" approach, focusing on long-term recurring cartridge sales and sustained revenue growth [5] - The recent contract reflects INBS's continued momentum following multiple deployments in various sectors, including transportation, construction, and mining [5]